New drug for recurrent glioblastoma with an unmethylated MGMT gene
Part of Cancer clinical trials.
This trial tests a new drug (KH617) for people whose glioblastoma has returned after the first round of standard treatment. The drug is hoped to slow or stop the tumor's growth. You must have a specific genetic marker (MGMT unmethylated) and be in fairly good health to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of brain tumor called glioblastoma, and it has come back for the first time after standard treatment.
- Your tumor has a specific genetic marker called 'MGMT unmethylated'.
- You are in generally good health (able to care for yourself, at least partly) and have enough bone marrow and organ function.
- You have not had chemotherapy, radiation, or other cancer drugs within 4 weeks before starting the trial.
- You do not have serious heart problems, HIV, active hepatitis, or other major uncontrolled conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CT-179 for people with glioblastoma, an aggressive type of brain cancer. The drug targets a protein that helps cancer cells grow, and the goal is to see if it is safe and whether it can slow the tumor down.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.